Health economic value of an innovation: delimiting the scope and framework of future market entry agreements

Journal of Market Access and Health Policy

Volumn 2, Issue 1, 2014, Pages

  Launois, Robert ^a   Navarrete, Lucia Fiestas ^a   Ethgen, Olivier ^b   Le Moine, Jean Gabriel ^a   Gatsinga, René ^a  

^a Evaluation Network for Health Economics (REES) France   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

comparative effectiveness research; cost effectiveness studies; pay for performance contract; risk sharing

Indexed keywords

EID: 85043597303     PISSN: None     EISSN: 20016689     Source Type: Journal    
DOI: 10.3402/jmahp.v2.24988     Document Type: Article

References (12)

1. JaroslawskiS, ToumiM.Market access agreements for pharmaceuticals in Europe: Diversity of approaches and underlying concepts. BMC Health Serv Res. 2011; 11: 259.
2. CarlsonJJ, SullivanSD, GarrisonLP, NeumannPJ, VeenstraDL.Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010; 96(3):179–90.
3. GarrisonLPJr, TowseA, BriggsA, de PouvourvilleG, GruegerJ, MohrPE et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: Report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013; 16(5):703–19. [PubMed Abstract].
4. AdamskiJ, GodmanB, Ofierska-SujkowskaG, OsinskaB, HerholzH, WendykowskaK et al. Risk sharing arrangements for pharmaceuticals: Potential considerations and recommendations for European payers. BMC Health Serv Res. 2010; 10: 153. [PubMed Abstract] [PubMed CentralFull Text].
5. GertlerPM, MartinezS, PremandP, RawlingsLB, VermeerschCMJ. Impact evaluation in practice. 2010; Washington, DC: The International Bank for Reconstruction and Development/The World Bank.
6. ContandriopoulosA-P, ChampagneF, DenisJ-L, PineaultR.L′évaluation dans le domaine de la santé: Concepts et méthodes. Bulletin. 1993; 33(1):12–17.
7. General Accounting OfficeUS. Designing evaluations. 1991; Washington, DC: US General Accounting Office.
8. GridchynaI. Utilisation de la norme juridique comme instrument de régulation du marché des médicaments innovants en Europe et en France. 2012; Bordeaux: Université Bordeaux 2.
9. RubinD.Estimating causal effects of treatments in randomized and nonrandomized studies. J Educ Psychol. 1974; 66(5):688–701.
10. MisdrahiD, DelgadoA, BoujuS, CometD, ChiarinyJF.[Rationale for the use of long-acting injectable risperidone: A survey of French psychiatrists]. Encephale. 2013; 39 Suppl 1: S8–14. [PubMed Abstract].
11. SchneeweissS, GagneJJ, GlynnRJ, RuhlM, RassenJA.Assessing the comparative effectiveness of newly marketed medications: Methodological challenges and implications for drug development. Clin Pharmacol Ther. 2011; 90(6):777–90. [PubMed Abstract].
12. BecquemontL, BordetR, CellierD.La médecine personnalisée: Comment passer du concept à l'integration dans un plan de développement clinique en vue d'une AMM?. Therapie. 2012; 67(4):339–48. [PubMed Abstract].